Celina Yung-Ai Lin Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Celina Yung-Ai Lin Lee has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Juliana Mara Serpeloni
State University of Londrina (UEL)
2 shared publications - Andresa Hiromi Sakai
Department of General Biology, Center for Biological Sciences, State University of Londrina, Londrina, Brazil
1 shared publication - Andressa Yuri Fujiike
Department of General Biology, Center of Biological Sciences, State University of Londrina (UEL), Londrina, PR, Brazil
1 shared publication - Aneli Melo Barbosa-Dekker
Beta-Glucan Produtos Farmoquímicos EIRELI, Lote 24A, Bloco Zircônia, Universidade Tecnológica Federal do Paraná, Câmpus Londrina, Londrina, Paraná, CEP: 86036-700, Brazil
1 shared publication - Anna Gabriele Prado dos Santos
Post-Graduation Program in Genetics and Molecular Biology, Department of General Biology, State University of Londrina, Londrina 86057-970, Brazil
1 shared publication - Arthur Barcelos Ribeiro
University of Franca, Franca, Brazil
1 shared publication
Latest Publications
- Open Access
- 23 September 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 374
A brachydin-rich fraction from Fridericia platyphylla induces apoptosis in breast cancer cells via upregulation of AIFM1 and BAX and reduced tumor growth in vivo
- 23 September 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 374
Open AccessA brachydin-rich fraction from Fridericia platyphylla induces apoptosis in breast cancer cells via upregulation of AIFM1 and BAX and reduced tumor growth in vivo
- 7 March 2022
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part A
- Vol. 85 (13) , 521-537
Anticancer effects of carboxymethylated (1→3)(1→6)-β-D-glucan (botryosphaeran) on multicellular tumor spheroids of MCF-7 cells as a model of breast cancer
Breast cancer is the most common cancer worldwide among the female population. The fungal exopolysaccharide botryosphaeran is a (1→3)(1→6)-β-D-glucan with limited solubility in water that can be promoted through carboxymethylation. Thus, the aim of this study was to examine in-vitro anticancer effects of carboxymethylated-botryosphaeran (CM-BOT) on breast cancer MCF-7 cells cultivated in multicellular tumor spheroids (MCTS). CM-BOT (≥ 600 µ/ml) decreased the viability (resazurin assay) of MCF-7 grown in monolayers after 24 hr incubation. Although CM-BOT did not markedly alter viability of MCTS in the resazurin assay after 24, 48 or 72 hr, CM-BOT ≥ 600 µg/ml produced cell-death by apoptosis after 72 hr utilizing the triple staining assay and labeling dead cells with propidium iodide, which can also be visualized on the architecture of MCTS. CM-BOT (1000 µg/ml) inhibited cell proliferation, which resulted in MCTSs with smaller diameters than controls. CM-BOT at all concentrations examined decreased the ability of MCF-7 to form colonies and to migrate in the extracellular matrix. This is the first report using MCTS-architecture to study anti-tumor effects of β-glucans. Our findings are important in the search for compounds for use in breast cancer therapy, or as adjuvants in reducing the adverse effects of mammary tumor chemotherapy.
- 7 March 2022
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part A
- Vol. 85 (13) , 521-537
Anticancer effects of carboxymethylated (1→3)(1→6)-β-D-glucan (botryosphaeran) on multicellular tumor spheroids of MCF-7 cells as a model of breast cancer
Breast cancer is the most common cancer worldwide among the female population. The fungal exopolysaccharide botryosphaeran is a (1→3)(1→6)-β-D-glucan with limited solubility in water that can be promoted through carboxymethylation. Thus, the aim of this study was to examine in-vitro anticancer effects of carboxymethylated-botryosphaeran (CM-BOT) on breast cancer MCF-7 cells cultivated in multicellular tumor spheroids (MCTS). CM-BOT (≥ 600 µ/ml) decreased the viability (resazurin assay) of MCF-7 grown in monolayers after 24 hr incubation. Although CM-BOT did not markedly alter viability of MCTS in the resazurin assay after 24, 48 or 72 hr, CM-BOT ≥ 600 µg/ml produced cell-death by apoptosis after 72 hr utilizing the triple staining assay and labeling dead cells with propidium iodide, which can also be visualized on the architecture of MCTS. CM-BOT (1000 µg/ml) inhibited cell proliferation, which resulted in MCTSs with smaller diameters than controls. CM-BOT at all concentrations examined decreased the ability of MCF-7 to form colonies and to migrate in the extracellular matrix. This is the first report using MCTS-architecture to study anti-tumor effects of β-glucans. Our findings are important in the search for compounds for use in breast cancer therapy, or as adjuvants in reducing the adverse effects of mammary tumor chemotherapy.